ライフサイエンスコーパス: S100beta

1 th glial fibrillary acidic protein (GFAP) or S100beta.

2 ia on astrocytes was also assessed with anti-S100beta.

3 s glial fibrillary acidic protein (GFAP) and S100beta.

4 the rod outer segments and its modulator is S100beta.

5 s at micromolar concentrations of Ca(2+) via S100beta.

6 into a form that only marginally responds to S100beta.

7 is less sensitive to activation by GCAP2 and S100beta.

8 and 5-HT2C receptors and an antibody against S100beta, a Schwann cell marker.

9 trations of Ca(2+), ROS-GC1 is stimulated by S100beta [also named calcium-dependent (CD) GCAP].

10 ually called S100b (S100betabeta or dimer of S100beta), also activates ROS-GC but that the Vmax of ac

11 Combined determination of S100beta and BIS had an incremental predictive value (AU

12 Combined determination of serum level of S100beta and BIS monitoring accurately predicts outcome

13 S100beta and BIS predicted 6-month mortality (log-rank s

14 The expression patterns of S100beta and glial fibrillary acidic protein (GFAP), wer

15 like (type IIa) cell immunopositive for both S100beta and glutamine synthetase (GS).

16 ge as indicated by a lack of change in MCAv, S100beta and neuron-specific enolase.

17 ed to show that these sites are specific for S100beta and not for another regulator of ROS-GC1, guany

18 ally regulates GFAP expression, as levels of S100beta and vimentin were not altered in the female amy

19 orm populations of immature astrocytes (>90% S100beta(+) and GFAP(+)) in large quantities.

20 GFAP) and S100 Calcium-Binding Protein beta (S100beta); and the inflammatory markers: Inducible Nitri

21 vimentin+, whereas astrocytes are GFAP+ and S100beta+, and the precursor cells are A2B5(+).

22 trypsin (ACT), interleukin-1beta (IL-1beta), S100beta, and butyrylcholinesterase (BChE).

23 ally displayed high immunostaining for GFAP, S100beta, and CD44, but low immunostaining for glutamine

24 port activity and immunoreactivity for GFAP, S100beta, and glutamate transporter GLT-1 within a few h

25 tudies revealed that CD-GCAP is identical to S100beta, another low-molecular-weight calcium-binding p

26 express markers, including Sox17, Sox10 and S100beta, are cloneable, have telomerase activity, and c

27 in pyramidal and stellate neurons, and more S100beta(+) astrocytes in the entorhinal cortex.

28 no effect on the total number of neurons or S100beta+ astrocytes in the ACC.

29 nge in expression of RAGE and HMGB1, but not S100beta, at sites of tissue damage.

30 lonic IL-6 levels as well as substance P and S100beta density in myenteric ganglia of HFD mice were i

31 nt protein in primary olfactory neurons, and S100beta-DsRed mice which express red fluorescent protei

32 limitans astrocytes, Iba-1(+) microglia and S100beta(+) ependymal cells expressed PLIN in the aging

33 and tyrosine hydroxylase to quantify nerves, S100beta for glia, Kit for interstitial cells of Cajal (

34 or eliminated TBI-induced increases in serum S100beta, GFAP, and neuron specific enolase.

35 Substance P (SP), S100beta, GFAP, and phosphorylated mitogen-activated pro

36 neurites), anti-HuC/HuD (neurons), and anti-S100beta (glia) in an allelic series of mice with mutati

37 labeling in white matter was associated with S100beta+/glial fibrillary acidic protein negative macro

38 f ROS-GC1 and on its activation by GCAP1 and S100beta; however, the mutated cyclase becomes more acti

39 rter 2, glial fibrillary acidic protein, and S100beta immunohistochemistry.

40 We previously showed vimentin and S100beta immunoreactivities through a network of meninge

41 Confocal mapping of calcium-binding protein S100beta immunoreactivity (S100beta-ir) and of the inter

42 Additionally, Schwann cell marker S100beta immunoreactivity was decreased or absent along

43 S100beta improved discriminations based on BIS (p = 0.00

44 gnificantly with levels of interleukin-6 and S100beta in fetal circulation.

45 rn cells colabeled with the astrocyte marker S100beta in higher numbers than when cells were generate

46 eas of tissue expression of RAGE, HMGB1, and S100beta in specific organs of mouse fetuses on E16.

47 Furthermore, the trophic factor S100beta induces Src-family kinase-mediated tyrosine pho

48 ain blood vessels, it was possible to detect S100beta-ir and vimentin-ir cell processes that cross th

49 In all tissues examined, S100beta-ir and vimentin-ir were primarily colocalized,

50 is suggested the probable means by which the S100beta-ir cells of the extraparenchymal tissues anatom

51 m-binding protein S100beta immunoreactivity (S100beta-ir) and of the intermediate filament vimentin-i

52 hotoreceptor guanylate cyclase activation by S100beta is validated by the identification of two S100b

53 erves, but not of degenerating nerves, while S100beta labeling was observed in the Schwann cells of a

54 Patients with S100beta level above 0.03 mug/l and BIS below 5.5 had a

55 s of cellular brain injury (NSE, BDNF, GFAP, S100beta, MCP1, VILIP-1, neurogranin); Factor 2 comprise

56 at its opposite ends is flanked by GCAP1 and S100beta modules.

57 al ganglia satellite cells, peripheral nerve S100beta+ myelinating Schwann cells, and peripheral nerv

58 However, GFAP and S100beta, often used for labeling astrocytes, were speci

59 The latter binds S100beta only marginally, yet it is critical for control

60 NSE, S100beta, or BIS alone predicted neurological outcome, w

61 type I nor 3alpha-HSD mRNAs are expressed in S100beta- or glial fibrillary acidic protein-positive gl

62 ), and BIS improved discriminations based on S100beta (p < 10(-5)).

63 s (-21%), and increased differentiation into S100beta-positive astrocytes (+23%).

64 related with MNTB growth and the presence of S100beta-positive astrocytes among MNTB neurons.

65 scent protein (EGFP) under the control of an S100beta promoter.

66 s 25% in the CTRL group, p = 0.01) and lower S100beta protein levels (189 +/- 42 vs 412 +/- 63 pg/mL,

67 lary reactivity (primary outcome), levels of S100beta protein, in vitro brain mitochondria functions,

68 (an endogenous RAGE antagonist), HMGB1, and S100beta protein.

69 he epidermal growth factor receptor and lack S100beta protein.

70 igen 2 (NG2) as a unique molecular marker of S100beta+ PSCs in skeletal muscle.

71 ta is validated by the identification of two S100beta-regulatory sites.

72 eatment of astrocytes with ACT, IL-1beta, or S100beta resulted in glial activation, as assessed by re

73 he DRG and sciatic nerve, ATF3 expression in S100beta(+) Schwann cells and increased expression of th

74 In this case, S100beta senses Ca(2+) and stimulates the cyclase.

75 S100beta senses increments in free Ca(2+) and stimulates

76 ) impulse and inhibits the catalytic module; S100beta senses the impulse and stimulates the catalytic

77 mbryos at E12.5, suggesting that the lack of S100beta staining and Schwann cell coverage in the p75 m

78 Each S100beta subunit (91 residues) contains four helixes (he

79 Further, the four helixes within each S100beta subunit form a splayed-type four-helix bundle (

80 53+/- or ink4a/arf+/- animals transgenic for S100beta-v-erbB) showed a similar tumor-specific down-re

81 reased the survival of mice allografted with S100beta-v-erbB/p53(-/-) glioma stem-like cells.

82 CSCs in a transgenic mouse model of glioma, S100beta-verbB;Trp53.

83 Privileged anatomical relationships of the S100beta/vimentin network with the glial fibrillary acid

84 Because 5-HT induces release of S100beta, we investigated the codependence of 5-HT recep

85 Levels of NSE and S100beta were higher in patients with poor outcomes comp

86 enolase (NSE) and neuron-enriched S100 beta (S100beta) were measured 48 h after CA.